Trevi Therapeutics ( (TRVI) ) has released its Q4 earnings. Here is a breakdown of the information Trevi Therapeutics presented to its investors.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Haduvio, an investigational therapy for chronic cough conditions, particularly in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).
In its latest earnings report, Trevi Therapeutics announced significant progress in its clinical trials, including positive topline data from the Phase 2a RIVER trial and the completion of enrollment in the Phase 2b CORAL trial. The company also reported a strong financial position with $107.6 million in cash and marketable securities, providing a cash runway into the second half of 2026.
Key financial highlights for the fourth quarter of 2024 include increased research and development expenses, driven by ongoing clinical trials, and a net loss of $11.4 million, up from $7.8 million in the same period in 2023. For the full year, Trevi reported a net loss of $47.9 million, reflecting its continued investment in clinical development.
Looking ahead, Trevi Therapeutics remains focused on advancing Haduvio through its clinical pipeline, with expectations for topline data from the Phase 2b CORAL trial in the second quarter of 2025. The company aims to address the unmet needs in chronic cough treatment, leveraging Haduvio’s unique mechanism of action.